AU594014B2
(en)
*
|
1984-03-21 |
1990-03-01 |
Research Corporation Technologies, Inc. |
Recombinant DNA molecules
|
US5718893A
(en)
*
|
1984-04-15 |
1998-02-17 |
Foster; Preston F. |
Use of G-CSF to reduce acute rejection
|
DE3680613D1
(de)
*
|
1985-02-08 |
1991-09-05 |
Chugai Pharmaceutical Co Ltd |
Menschlicher granuloxcyt-kolonie-stimulierungsfaktor.
|
US5532341A
(en)
*
|
1985-03-28 |
1996-07-02 |
Sloan-Kettering Institute For Cancer Research |
Human pluripotent hematopoietic colony stimulating factor
|
US5078996A
(en)
*
|
1985-08-16 |
1992-01-07 |
Immunex Corporation |
Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
|
US6004548A
(en)
|
1985-08-23 |
1999-12-21 |
Amgen, Inc. |
Analogs of pluripotent granulocyte colony-stimulating factor
|
US4810643A
(en)
*
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
NZ218336A
(en)
*
|
1985-12-09 |
1991-08-27 |
Kirin Amgen Inc |
Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf)
|
DK203187A
(da)
*
|
1986-04-22 |
1987-10-23 |
Immunex Corp |
Human g-csf proteinekspression
|
GR871067B
(en)
*
|
1986-07-18 |
1987-11-19 |
Chugai Pharmaceutical Co Ltd |
Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
|
US5186931A
(en)
*
|
1986-08-06 |
1993-02-16 |
Ajinomoto Co., Inc. |
Composition and method for supporting bone marrow transplantation
|
EP0256843A1
(en)
*
|
1986-08-11 |
1988-02-24 |
Cetus Corporation |
Expression of g-csf and muteins thereof and their use
|
JPH0618781B2
(ja)
*
|
1986-10-18 |
1994-03-16 |
中外製薬株式会社 |
感染症治療剤
|
US6238889B1
(en)
*
|
1986-12-16 |
2001-05-29 |
Dsm N.V. |
Molecular cloning and expression of the Pro8 isoform of human IL-3
|
US5362853A
(en)
*
|
1986-12-23 |
1994-11-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Polypeptide derivatives of human granulocyte colony stimulating factor
|
US5714581A
(en)
*
|
1986-12-23 |
1998-02-03 |
Kyowa Hakko Kogyo Co., Ltd. |
Polypeptide derivatives of human granulocyte colony stimulating factor
|
JP2618618B2
(ja)
*
|
1988-03-04 |
1997-06-11 |
協和醗酵工業株式会社 |
抗g−csf誘導体、nd28モノクローナル抗体
|
US5194592A
(en)
*
|
1986-12-23 |
1993-03-16 |
Kyowa Hakko Kogyo Co. Ltd. |
Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor
|
DK174044B1
(da)
*
|
1986-12-23 |
2002-05-06 |
Kyowa Hakko Kogyo Kk |
Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid.......
|
US5214132A
(en)
*
|
1986-12-23 |
1993-05-25 |
Kyowa Hakko Kogyo Co., Ltd. |
Polypeptide derivatives of human granulocyte colony stimulating factor
|
US6384194B1
(en)
*
|
1987-12-16 |
2002-05-07 |
Dsm N.V. |
Expression and purification of human interleukin-3 and muteins thereof
|
GB2213821B
(en)
*
|
1987-12-23 |
1992-01-02 |
British Bio Technology |
Synthetic human granulocyte colony stimulating factor gene
|
US5599690A
(en)
*
|
1988-02-01 |
1997-02-04 |
Amgen Inc. |
Control of norleucine incorporation into recombinant proteins
|
CA1329119C
(en)
*
|
1988-03-29 |
1994-05-03 |
Milton David Goldenberg |
Cytotoxic therapy
|
US20030232010A2
(en)
*
|
1988-03-29 |
2003-12-18 |
Immunomedics, Inc. |
Improved cytotoxic therapy
|
EP0719860B1
(en)
*
|
1988-05-13 |
2009-12-16 |
Amgen Inc. |
Process for isolating and purifying G-CSF
|
US5070013A
(en)
*
|
1988-05-31 |
1991-12-03 |
Schering Corporation |
Immunochemical assay for human granulocyte-macrophage colony stimulating factor
|
US5082774A
(en)
*
|
1988-08-30 |
1992-01-21 |
The General Hospital Corporation |
Recombinant human nerve growth factor
|
US5218092A
(en)
*
|
1988-09-29 |
1993-06-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
|
US5104651A
(en)
*
|
1988-12-16 |
1992-04-14 |
Amgen Inc. |
Stabilized hydrophobic protein formulations of g-csf
|
US6166183A
(en)
*
|
1992-11-30 |
2000-12-26 |
Kirin-Amgen, Inc. |
Chemically-modified G-CSF
|
US20020177688A1
(en)
*
|
1988-12-22 |
2002-11-28 |
Kirin-Amgen, Inc., |
Chemically-modified G-CSF
|
ATE135370T1
(de)
*
|
1988-12-22 |
1996-03-15 |
Kirin Amgen Inc |
Chemisch modifizierte granulocytenkolonie erregender faktor
|
WO1990012877A1
(en)
*
|
1989-04-19 |
1990-11-01 |
Cetus Corporation |
Multifunctional m-csf proteins and genes encoding therefor
|
US6254861B1
(en)
*
|
1989-05-23 |
2001-07-03 |
Chandra Choudhury |
Hematopoietic growth factor derived from T lymphocytes
|
US5605822A
(en)
*
|
1989-06-15 |
1997-02-25 |
The Regents Of The University Of Michigan |
Methods, compositions and devices for growing human hematopoietic cells
|
US5635386A
(en)
*
|
1989-06-15 |
1997-06-03 |
The Regents Of The University Of Michigan |
Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
|
US5763266A
(en)
*
|
1989-06-15 |
1998-06-09 |
The Regents Of The University Of Michigan |
Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells
|
DE69029856T2
(de)
*
|
1989-06-15 |
1997-09-04 |
Univ Michigan |
Verfahren, zubereitungen und anordnungen für zellzucht
|
US5665543A
(en)
*
|
1989-07-18 |
1997-09-09 |
Oncogene Science, Inc. |
Method of discovering chemicals capable of functioning as gene expression modulators
|
US6203976B1
(en)
|
1989-07-18 |
2001-03-20 |
Osi Pharmaceuticals, Inc. |
Methods of preparing compositions comprising chemicals capable of transcriptional modulation
|
US5776502A
(en)
|
1989-07-18 |
1998-07-07 |
Oncogene Science, Inc. |
Methods of transcriptionally modulating gene expression
|
US5580722A
(en)
*
|
1989-07-18 |
1996-12-03 |
Oncogene Science, Inc. |
Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
|
AU641949B2
(en)
*
|
1989-10-10 |
1993-10-07 |
Amgen, Inc. |
Compositions and methods for treating or preventing infections in canine and feline animals
|
CA2025181A1
(en)
*
|
1989-10-12 |
1991-04-13 |
William G. Weisburg |
Nucleic acid probes and methods for detecting fungi
|
US20040181044A1
(en)
*
|
1989-10-16 |
2004-09-16 |
Zsebo Krisztina M. |
Method of stimulating growth of epithelial cells by administering stem cell factor
|
US6852313B1
(en)
|
1989-10-16 |
2005-02-08 |
Amgen Inc. |
Method of stimulating growth of melanocyte cells by administering stem cell factor
|
EP0423980B1
(en)
*
|
1989-10-16 |
2000-07-12 |
Amgen Inc. |
Stem cell factor
|
ZA907921B
(en)
|
1989-10-16 |
1991-08-28 |
Amgen Inc |
Stem cell factor
|
AU6541090A
(en)
*
|
1989-10-16 |
1991-05-16 |
Amgen, Inc. |
Stem cell factor
|
US7144731B2
(en)
*
|
1989-10-16 |
2006-12-05 |
Amgen Inc. |
SCF antibody compositions and methods of using the same
|
US5214133A
(en)
*
|
1989-11-17 |
1993-05-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
SCL: a hematopoietic growth and differentiation factor
|
US5132212A
(en)
*
|
1989-11-17 |
1992-07-21 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Scl gene, and a hematopoietic growth and differentiation factor encoded thereby
|
JPH04218000A
(ja)
*
|
1990-02-13 |
1992-08-07 |
Kirin Amgen Inc |
修飾ポリペプチド
|
US5147799A
(en)
*
|
1990-04-25 |
1992-09-15 |
Isia Bursuker |
Repopulation of macrophages and granulocytes using transforming growth factor-beta
|
GB9107846D0
(en)
*
|
1990-04-30 |
1991-05-29 |
Ici Plc |
Polypeptides
|
US5399345A
(en)
*
|
1990-05-08 |
1995-03-21 |
Boehringer Mannheim, Gmbh |
Muteins of the granulocyte colony stimulating factor
|
US5258367A
(en)
*
|
1990-06-29 |
1993-11-02 |
University Of Florida |
Uteroferrin and rose proteins for stimulating hematopoietic cells
|
IE912365A1
(en)
*
|
1990-07-23 |
1992-01-29 |
Zeneca Ltd |
Continuous release pharmaceutical compositions
|
AU1462392A
(en)
*
|
1991-02-22 |
1992-09-15 |
Amgen, Inc. |
Use of gm-csf and g-csf to promote accelerated wound healing
|
DE69233336T2
(de)
*
|
1991-02-26 |
2005-03-31 |
Astrazeneca Ab |
Vektor
|
US6565841B1
(en)
|
1991-03-15 |
2003-05-20 |
Amgen, Inc. |
Pulmonary administration of granulocyte colony stimulating factor
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US6361976B1
(en)
|
1992-11-24 |
2002-03-26 |
S. Christopher Bauer |
Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production
|
US5738849A
(en)
*
|
1992-11-24 |
1998-04-14 |
G. D. Searle & Co. |
Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
|
US6057133A
(en)
*
|
1992-11-24 |
2000-05-02 |
G. D. Searle |
Multivariant human IL-3 fusion proteins and their recombinant production
|
US7091319B1
(en)
|
1992-11-24 |
2006-08-15 |
Bauer S Christopher |
IL-3 variant hematopoiesis fusion protein
|
US6153183A
(en)
*
|
1992-11-24 |
2000-11-28 |
G. D. Searle & Company |
Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
|
US5772992A
(en)
*
|
1992-11-24 |
1998-06-30 |
G.D. Searle & Co. |
Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
|
US6403076B1
(en)
|
1992-11-24 |
2002-06-11 |
S. Christopher Bauer |
Compositions for increasing hematopoiesis with interleukin-3 mutants
|
US6361977B1
(en)
|
1992-11-24 |
2002-03-26 |
S. Christopher Bauer |
Methods of using multivariant IL-3 hematopoiesis fusion protein
|
US6413509B1
(en)
|
1992-11-24 |
2002-07-02 |
S. Christopher Bauer |
Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors
|
AU2007200247B2
(en)
*
|
1993-01-28 |
2011-03-10 |
Amgen Inc. |
G-CSF analog compositions
|
US5581476A
(en)
*
|
1993-01-28 |
1996-12-03 |
Amgen Inc. |
Computer-based methods and articles of manufacture for preparing G-CSF analogs
|
DE69430369T2
(de)
|
1993-09-15 |
2002-10-17 |
Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville |
Rekombinanter alphavirus vektor
|
US5874075A
(en)
*
|
1993-10-06 |
1999-02-23 |
Amgen Inc. |
Stable protein: phospholipid compositions and methods
|
US20050059149A1
(en)
*
|
1993-11-22 |
2005-03-17 |
Bauer S. Christopher |
Methods of ex-vivo expansion of hematopoeitic cells using multivariant IL-3 hematopoiesis chimera proteins
|
CA2139385C
(en)
*
|
1994-02-04 |
2001-12-25 |
Gottfried Alber |
Products containing g-csf and tnf binding protein
|
US6242417B1
(en)
|
1994-03-08 |
2001-06-05 |
Somatogen, Inc. |
Stabilized compositions containing hemoglobin
|
US5631219A
(en)
*
|
1994-03-08 |
1997-05-20 |
Somatogen, Inc. |
Method of stimulating hematopoiesis with hemoglobin
|
WO1995026746A1
(en)
*
|
1994-03-31 |
1995-10-12 |
Amgen Inc. |
Compositions and methods for stimulating megakaryocyte growth and differentiation
|
US5795569A
(en)
*
|
1994-03-31 |
1998-08-18 |
Amgen Inc. |
Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
|
US5536495A
(en)
*
|
1994-04-15 |
1996-07-16 |
Foster; Preston F. |
Use of G-CSF to reduce acute rejection
|
US20030053982A1
(en)
*
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
US5824784A
(en)
*
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
US6100070A
(en)
*
|
1995-10-05 |
2000-08-08 |
G. D. Searle & Co. |
G-CSF receptor agonists
|
US6066318A
(en)
*
|
1995-10-05 |
2000-05-23 |
G.D. Searle & Co. |
Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
|
ATE386811T1
(de)
|
1996-04-05 |
2008-03-15 |
Novartis Vaccines & Diagnostic |
Alphaviren-vektors mit eine reduzierte inhibierung der synthese von zellmakromolekülen
|
EP2298900A1
(en)
|
1996-09-17 |
2011-03-23 |
Novartis Vaccines and Diagnostics, Inc. |
Compositions and methods for treating intracellular diseases
|
US6162426A
(en)
*
|
1997-05-05 |
2000-12-19 |
La Gamma; Edmund F. |
Use of G-CSF to enhance the immune system in neonates
|
ES2297889T3
(es)
|
1997-07-14 |
2008-05-01 |
Bolder Biotechnology, Inc. |
Derivados de hormona de crecimiento y proteinas relacionadas.
|
US7495087B2
(en)
|
1997-07-14 |
2009-02-24 |
Bolder Biotechnology, Inc. |
Cysteine muteins in the C-D loop of human interleukin-11
|
US7153943B2
(en)
|
1997-07-14 |
2006-12-26 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins, and methods of use thereof
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
US6017876A
(en)
|
1997-08-15 |
2000-01-25 |
Amgen Inc. |
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
|
WO1999017798A1
(en)
*
|
1997-10-02 |
1999-04-15 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections
|
US20020034819A1
(en)
*
|
1998-02-23 |
2002-03-21 |
Alan K. Smith |
Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses
|
US6541033B1
(en)
|
1998-06-30 |
2003-04-01 |
Amgen Inc. |
Thermosensitive biodegradable hydrogels for sustained delivery of leptin
|
CN1101403C
(zh)
*
|
1998-07-13 |
2003-02-12 |
金磊 |
粒细胞集落刺激因子的制备
|
US6979442B1
(en)
|
1998-08-17 |
2005-12-27 |
Pfizer Inc. |
Stabilized protein compositions
|
US5999474A
(en)
|
1998-10-01 |
1999-12-07 |
Monolithic System Tech Inc |
Method and apparatus for complete hiding of the refresh of a semiconductor memory
|
US6420339B1
(en)
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
US6451346B1
(en)
*
|
1998-12-23 |
2002-09-17 |
Amgen Inc |
Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
|
US6245740B1
(en)
|
1998-12-23 |
2001-06-12 |
Amgen Inc. |
Polyol:oil suspensions for the sustained release of proteins
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
US6602705B1
(en)
|
1998-12-31 |
2003-08-05 |
Chiron Corporation |
Expression of HIV polypeptides and production of virus-like particles
|
US7208473B2
(en)
*
|
1999-01-06 |
2007-04-24 |
Xencor, Inc. |
Nucleic acids and protein variants of hG-CSF with granulopoietic activity
|
US6627186B1
(en)
|
1999-01-06 |
2003-09-30 |
Xencor |
Nucleic acids and protein variants of hG-CSF with granulopoietic activity
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
DK1146913T3
(da)
|
1999-01-19 |
2009-05-04 |
Molecular Insight Pharm Inc |
Konjugerede granulocyt koloni-stimulerende faktorer for targeting og afbildning af infektion og inflammation
|
CN1376164A
(zh)
*
|
1999-01-29 |
2002-10-23 |
霍夫曼-拉罗奇有限公司 |
Gcsf缀合物
|
US6365583B1
(en)
|
1999-02-02 |
2002-04-02 |
Anormed, Inc. |
Methods to enhance white blood cell count
|
KR100356140B1
(ko)
*
|
1999-07-08 |
2002-10-19 |
한미약품공업 주식회사 |
인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
|
US8106098B2
(en)
*
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
AU784195B2
(en)
|
1999-11-12 |
2006-02-16 |
Baxter Biotech Technology S.A.R.L. |
Reduced side-effect hemoglobin compositions
|
AU782580B2
(en)
|
2000-01-10 |
2005-08-11 |
Maxygen, Inc. |
G-CSF conjugates
|
US6555660B2
(en)
*
|
2000-01-10 |
2003-04-29 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
US6831158B2
(en)
*
|
2000-01-10 |
2004-12-14 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
US6646110B2
(en)
*
|
2000-01-10 |
2003-11-11 |
Maxygen Holdings Ltd. |
G-CSF polypeptides and conjugates
|
EP1129720B1
(en)
|
2000-02-29 |
2004-06-23 |
Pfizer Products Inc. |
Stabilized granulocyte colony stimulating factor
|
US20020022627A1
(en)
*
|
2000-03-31 |
2002-02-21 |
Dannenberg Andrew J. |
Inhibition of cyclooxygenase-2activity
|
EP1278544A4
(en)
|
2000-04-12 |
2004-08-18 |
Human Genome Sciences Inc |
ALBUMIN FUSION PROTEINS
|
US8435939B2
(en)
|
2000-09-05 |
2013-05-07 |
Biokine Therapeutics Ltd. |
Polypeptide anti-HIV agent containing the same
|
EP1317537B1
(en)
*
|
2000-09-08 |
2006-12-20 |
Massachusetts Institute Of Technology |
G-csf analog compositions and methods
|
EP1195437A1
(en)
*
|
2000-10-04 |
2002-04-10 |
Mitsui Chemicals, Inc. |
Process for the recombinant production of proteins using a Plac/Np hybrid promoter
|
US7812169B2
(en)
*
|
2000-11-30 |
2010-10-12 |
The Children's Medical Center Corporation |
Method of synthesis of 4-amino-thalidomide enantiomers
|
EP1229045A1
(en)
|
2001-02-01 |
2002-08-07 |
Institut Curie |
Universal carrier for targeting molecules to Gb3 receptor expressing cells
|
WO2002069232A2
(en)
|
2001-02-19 |
2002-09-06 |
Merck Patent Gmbh |
Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
|
FR2820979B1
(fr)
|
2001-02-22 |
2004-03-12 |
Didier Pourquier |
Nouvelle application therapeutique du g-csf
|
US6956023B1
(en)
|
2001-04-19 |
2005-10-18 |
University Of Florida |
Materials and methods for providing nutrition to neonates
|
EP2292772A1
(en)
|
2001-07-05 |
2011-03-09 |
Novartis Vaccines and Diagnostics, Inc. |
HIV vaccination with a DNA encoding a HIV polypeptide and a HIV polypeptide
|
US7211659B2
(en)
|
2001-07-05 |
2007-05-01 |
Chiron Corporation |
Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
|
EP1425304B9
(en)
|
2001-07-11 |
2010-09-08 |
Maxygen, Inc. |
G-csf conjugates
|
SI1411918T1
(sl)
*
|
2001-07-31 |
2012-04-30 |
Genzyme Global S A R L |
Postopki za mobilizacijo progenitorskih/matičnih celic
|
US7169750B2
(en)
*
|
2001-07-31 |
2007-01-30 |
Anormed, Inc. |
Methods to mobilize progenitor/stem cells
|
US20030104996A1
(en)
*
|
2001-08-30 |
2003-06-05 |
Tiansheng Li |
L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
|
IL161251A0
(en)
|
2001-10-10 |
2004-09-27 |
Neose Technologies Inc |
Remodeling and glycoconjugation of peptides
|
DK2279753T3
(en)
|
2001-10-10 |
2015-11-23 |
Novo Nordisk As |
The conversion of peptides and glycokonjugering
|
SI21102A
(sl)
|
2001-12-19 |
2003-06-30 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
|
EP2277910A1
(en)
|
2001-12-21 |
2011-01-26 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
KR20030062854A
(ko)
*
|
2002-01-21 |
2003-07-28 |
주식회사 엘지생명과학 |
분비형 벡터를 이용한 효모에서의 재조합 단백질의 제조방법
|
AU2003210052A1
(en)
*
|
2002-03-20 |
2003-09-29 |
Biopolymed Inc. |
Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
AU2003228751A1
(en)
|
2002-05-01 |
2003-11-17 |
Cell Genesys, Inc. |
Lentiviral vector particles resistant to complement inactivation
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
EP1556033A4
(en)
|
2002-05-17 |
2006-05-31 |
Celgene Corp |
METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
DE60331537D1
(de)
|
2002-05-17 |
2010-04-15 |
Celgene Corp |
Kombinationen zur behandlung von multiplem myelom
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
US7081443B2
(en)
*
|
2002-05-21 |
2006-07-25 |
Korea Advanced Institutes Of Science And Technology (Kaist) |
Chimeric comp-ang1 molecule
|
WO2004001056A1
(en)
*
|
2002-06-24 |
2003-12-31 |
Dr. Reddy's Laboratories Ltd. |
Process for preparing g-csf
|
SI21273A
(sl)
*
|
2002-07-31 |
2004-02-29 |
LEK farmacevtska dru�ba d.d. |
Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
|
AU2003261723A1
(en)
|
2002-08-27 |
2004-03-19 |
Takeda Chemical Industries, Ltd. |
Cxcr4 antagonist and use thereof
|
DE60332358D1
(de)
*
|
2002-09-09 |
2010-06-10 |
Hanall Pharmaceutical Co Ltd |
Protease-resistente modifizierte interferon alpha polypeptide
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
CA2501936A1
(en)
*
|
2002-10-15 |
2004-04-29 |
Celgene Corporation |
Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
EP1900369A1
(en)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
CN1735412A
(zh)
|
2002-11-06 |
2006-02-15 |
细胞基因公司 |
利用选择性细胞因子抑制药物治疗和控制癌症和其它疾病的方法和组合物
|
WO2004047770A2
(en)
*
|
2002-11-26 |
2004-06-10 |
Anthrogenesis Corporation |
Cytotherapeutics, cytotherapeutic units and methods for treatments using them
|
US7785601B2
(en)
*
|
2002-12-31 |
2010-08-31 |
Sygnis Bioscience Gmbh & Co. Kg |
Methods of treating neurological conditions with hematopoietic growth factors
|
US7695723B2
(en)
*
|
2002-12-31 |
2010-04-13 |
Sygnis Bioscience Gmbh & Co. Kg |
Methods of treating neurological conditions with hematopoietic growth factors
|
AU2003299430B2
(en)
*
|
2002-12-31 |
2009-01-08 |
Neurovision-Pharma Gmbh |
Methods of treating neurological conditions with hematopoeitic growth factors
|
NZ542127A
(en)
*
|
2003-02-13 |
2008-04-30 |
Anthrogenesis Corp |
Use of umbilical cord blood to treat individuals having a disease, disorder or condition
|
NZ542671A
(en)
|
2003-03-12 |
2008-12-24 |
Celgene Corp |
7-Amido-isoindolyl compounds and their pharmaceutical uses
|
WO2004091495A2
(en)
*
|
2003-04-09 |
2004-10-28 |
University Of Utah Research Foundation |
Compositions and methods related to production of erythropoietin
|
MXPA05010773A
(es)
|
2003-04-09 |
2005-12-12 |
Neose Technologies Inc |
Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
|
CN101941964A
(zh)
*
|
2003-04-22 |
2011-01-12 |
阿诺麦德股份有限公司 |
具有促进功效的趋化因子受体结合的杂环化合物
|
US7501518B2
(en)
*
|
2003-04-22 |
2009-03-10 |
Genzyme Corporation |
Methods of making 2,6-diaryl piperidine derivatives
|
EP1667706A4
(en)
*
|
2003-08-22 |
2009-06-24 |
Queensland Inst Med Res |
G-CSF DERIVATIVE FOR INDUCING IMMUNOLOGICAL TOLERANCE
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US7220407B2
(en)
*
|
2003-10-27 |
2007-05-22 |
Amgen Inc. |
G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
|
AU2004288714A1
(en)
|
2003-11-06 |
2005-05-26 |
Celgene Corporation |
Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
|
EP1694328A4
(en)
*
|
2003-12-02 |
2010-02-17 |
Celgene Corp |
METHOD AND COMPOSITIONS FOR THE TREATMENT AND SUPPLY OF HEMOGLOBINOPATHY AND ANEMIA
|
US20060003008A1
(en)
|
2003-12-30 |
2006-01-05 |
Gibson John W |
Polymeric devices for controlled release of active agents
|
CA2553040A1
(en)
*
|
2004-02-02 |
2005-08-18 |
Ambrx, Inc. |
Modified human four helical bundle polypeptides and their uses
|
SE0400942D0
(sv)
*
|
2004-04-08 |
2004-04-08 |
Henrik Arnberg |
Composition and method
|
EP1744749A4
(en)
*
|
2004-04-14 |
2009-04-22 |
Celgene Corp |
METHODS OF USE AND COMPOSITION COMPRISING IMMUNOMODULATOR COMPOUNDS FOR THE TREATMENT AND CARE OF MYELODYSPLASIC SYNDROMES
|
BRPI0418743A
(pt)
*
|
2004-04-14 |
2007-09-18 |
Celgene Corp |
métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
|
EP1586334A1
(en)
*
|
2004-04-15 |
2005-10-19 |
TRASTEC scpa |
G-CSF conjugates with peg
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
JP2008513356A
(ja)
*
|
2004-08-09 |
2008-05-01 |
アリオス バイオファーマ インク. |
合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
|
WO2006020891A2
(en)
*
|
2004-08-13 |
2006-02-23 |
Anormed Inc. |
Chemokine combinations to mobilize progenitor/stem cells
|
EP1796457B1
(en)
*
|
2004-09-07 |
2011-11-23 |
Velico Medical, Inc. |
Apparatus for prolonging survival of platelets
|
EP1819355A4
(en)
|
2004-09-28 |
2009-08-12 |
Genexel Sein Inc |
METHOD OF USE OF A CHIMERIC COILED COIL MOLECULE
|
AU2006304496B2
(en)
*
|
2004-10-15 |
2013-07-11 |
Velico Medical, Inc. |
Compositions and methods for prolonging survival of platelets
|
GB0505353D0
(en)
|
2005-03-16 |
2005-04-20 |
Chem Technologies Ltd E |
Treatment process for concrete
|
CA2585672A1
(en)
|
2004-11-01 |
2006-05-11 |
Novartis Vaccines And Diagnostics Inc. |
Combination approaches for generating immune responses
|
US20060153799A1
(en)
*
|
2004-11-05 |
2006-07-13 |
Northwestern University |
Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
|
EP1828241A1
(en)
*
|
2004-12-23 |
2007-09-05 |
Laboratoires Serono S.A. |
G-csf polypeptides and uses thereof
|
EP1858543B1
(en)
|
2005-01-10 |
2013-11-27 |
BioGeneriX AG |
Glycopegylated granulocyte colony stimulating factor
|
JP5735194B2
(ja)
|
2005-01-25 |
2015-06-17 |
セル セラピューティクス インコーポレーテッド |
改善された生体内半減期を有する生物学的に活性なタンパク質
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
CN101193658B
(zh)
|
2005-06-01 |
2011-08-31 |
马克西根控股公司 |
聚乙二醇化g-csf多肽及其产生方法
|
EP1739179A1
(en)
|
2005-06-30 |
2007-01-03 |
Octapharma AG |
Serum-free stable transfection and production of recombinant human proteins in human cell lines
|
DE102005033250A1
(de)
|
2005-07-15 |
2007-01-18 |
Bioceuticals Arzneimittel Ag |
Verfahren zur Reinigung von G-CSF
|
KR100735784B1
(ko)
*
|
2005-07-20 |
2007-07-06 |
재단법인 목암생명공학연구소 |
인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
|
JP2009503111A
(ja)
*
|
2005-08-04 |
2009-01-29 |
ネクター セラピューティックス エイエル,コーポレイション |
G−csf部分および重合体の複合体
|
US8580814B2
(en)
*
|
2006-04-03 |
2013-11-12 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
US20100035941A1
(en)
*
|
2006-02-24 |
2010-02-11 |
Bridger Gary J |
Methods for increasing blood flow and/or promoting tissue regeneration
|
DE102006009437A1
(de)
|
2006-03-01 |
2007-09-13 |
Bioceuticals Arzneimittel Ag |
G-CSF-Flüssigformulierung
|
WO2007102814A2
(en)
*
|
2006-03-07 |
2007-09-13 |
Regenetech, Inc. |
Recombinant mammalian molecules and method for production thereof
|
GB0605684D0
(en)
*
|
2006-03-21 |
2006-05-03 |
Sicor Biotech Uab |
Method For Purifying Granulocyte-Colony Stimulating Factor
|
US20100196336A1
(en)
|
2006-05-23 |
2010-08-05 |
Dongsu Park |
Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
|
MX2008015775A
(es)
|
2006-06-12 |
2009-04-17 |
Sunesis Pharmaceuticals Inc |
Compuestos y composiciones para tratamiento de cancer.
|
WO2008016702A2
(en)
*
|
2006-08-02 |
2008-02-07 |
Sunesis Pharmaceuticals, Inc. |
Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic
|
CL2007002218A1
(es)
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
CA2659337A1
(en)
*
|
2006-08-07 |
2008-02-14 |
Genzyme Corporation |
Combination therapy
|
US8455450B2
(en)
|
2006-12-21 |
2013-06-04 |
Biokine Therapeutics Ltd. |
Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof
|
WO2008096370A2
(en)
*
|
2007-02-05 |
2008-08-14 |
Natco Pharma Limited |
An efficient and novel purification method of recombinant hg-csf
|
AU2008247815B2
(en)
*
|
2007-05-02 |
2012-09-06 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
WO2009023402A2
(en)
*
|
2007-07-17 |
2009-02-19 |
Acea Biosciences Inc. |
Heterocyclic compounds and uses as anticancer agents
|
US7893045B2
(en)
|
2007-08-07 |
2011-02-22 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
EP2185689A2
(en)
|
2007-08-09 |
2010-05-19 |
Genzyme Corporation |
Method of treating autoimmune disease with mesenchymal stem cells
|
BRPI0815280A2
(pt)
|
2007-08-27 |
2018-11-27 |
Biogenerix Ag |
medicamento que compreende uma formulação líquida aquosa de g-csf, receptáculo para a administração de medicamentos líquidos, seringa ou ampola, kit para a administração parenteral de g-csf
|
JP5570988B2
(ja)
|
2007-08-27 |
2014-08-13 |
ラティオファーム ゲーエムベーハー |
G−csf結合体の液体調製物
|
WO2009046015A2
(en)
*
|
2007-09-30 |
2009-04-09 |
University Of Florida Research Foundation, Inc. |
Combination therapies for treating type 1 diabetes
|
KR100921226B1
(ko)
|
2007-10-04 |
2009-10-12 |
학교법인 선목학원 |
사람 혈액의 과립구집락자극인자(hG-CSF) 유전자를 내장하는 레트로바이러스 발현벡터 및 이에 의해 형질전환된 가금
|
US20090155838A1
(en)
*
|
2007-11-28 |
2009-06-18 |
Smart Tube, Inc. |
Devices, systems and methods for the collection, stimulation, stabilization, and analysis of a biological sample
|
AU2008335772B2
(en)
|
2007-12-10 |
2014-11-27 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3- methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1- (2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
|
CN101939443B
(zh)
|
2008-02-08 |
2014-01-29 |
Ambrx公司 |
经修饰瘦素多肽和其用途
|
WO2009134396A2
(en)
*
|
2008-04-30 |
2009-11-05 |
Neutron Row |
Methods of using corticotropin-releasing factor for the treatment of cancer
|
MX363023B
(es)
|
2008-05-15 |
2019-03-05 |
Celgene Corp |
Formulaciones orales de analogos de citidina y metodos para usar los mismos.
|
PT2318029T
(pt)
*
|
2008-07-23 |
2018-01-10 |
Ambrx Inc |
Polipéptidos de g-csf bovino modificados e suas utilizações
|
US9155780B2
(en)
|
2009-02-11 |
2015-10-13 |
Yeda Research And Development Co. Ltd. |
Short beta-defensin-derived peptides
|
JP5645816B2
(ja)
|
2009-05-25 |
2014-12-24 |
国立大学法人東京工業大学 |
中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
|
ES2462517T3
(es)
|
2009-06-14 |
2014-05-23 |
Biokine Therapeutics Ltd. |
Terapia con péptidos para aumentar los niveles de plaquetas
|
KR101741859B1
(ko)
|
2009-06-22 |
2017-06-15 |
암젠 인크 |
화학적으로 조절된 산화환원 상태를 사용한 단백질의 재폴딩
|
KR20120124353A
(ko)
|
2009-06-24 |
2012-11-13 |
스티븐 에반스-프레케 |
암 치료를 위해 코르티코트로핀 방출인자를 사용하는 방법
|
WO2010151688A2
(en)
|
2009-06-25 |
2010-12-29 |
Amgen Inc. |
Capture purification processes for proteins expressed in a non-mammalian system
|
TW201120037A
(en)
|
2009-10-26 |
2011-06-16 |
Sunesis Pharmaceuticals Inc |
Compounds and methods for treatment of cancer
|
US20110129858A1
(en)
*
|
2009-11-27 |
2011-06-02 |
Changhua Christian Hospital |
Prognosis Biomarker for Evaluating the Cure Level of Stroke Patient and a Method thereof
|
US20120283171A1
(en)
|
2009-12-21 |
2012-11-08 |
Ambrx, Inc. |
Modified bovine somatotropin polypeptides and their uses
|
RS53010B
(en)
|
2009-12-31 |
2014-04-30 |
Arven Ilac Sanayi Ve Ticaret A.S. |
NEW PROCEDURE FOR PREPARATION OF G-CSF (GRANULOCITE COLONY STIMULATION FACTOR)
|
RU2012140020A
(ru)
|
2010-02-19 |
2014-03-27 |
Ацея Байосайенсиз Инк. |
Гетероциклические соединения и их применение в качестве противораковых средств
|
JP5840148B2
(ja)
|
2010-03-04 |
2016-01-06 |
フェニックス インク. |
変性させることなく可溶性組換えインターフェロンタンパク質を産生する方法
|
MX2012010367A
(es)
*
|
2010-03-12 |
2012-11-23 |
Celgene Corp |
Metodos para el tratamiento de linfomas no hodgkin que usan lenalidomida y biomarcadores de genes y proteinas como un predictor.
|
CA2794740C
(en)
|
2010-04-01 |
2019-12-31 |
Pfenex Inc. |
Methods for g-csf production in a pseudomonas host cell
|
EP3578205A1
(en)
*
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
EP2621515B1
(en)
|
2010-09-28 |
2017-03-29 |
Aegerion Pharmaceuticals, Inc. |
A chimeric seal-human leptin polypeptide with increased solubility
|
US20140031325A1
(en)
|
2010-12-06 |
2014-01-30 |
Celgene Corporation |
Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
CN103338753A
(zh)
|
2011-01-31 |
2013-10-02 |
细胞基因公司 |
胞苷类似物的药物组合物及其使用方法
|
DK2683708T3
(da)
|
2011-03-11 |
2018-01-29 |
Celgene Corp |
Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
|
BR112013023280A2
(pt)
|
2011-03-11 |
2017-09-19 |
Celgene Corp |
uso de 3-(5-amino-2-metil-4-oxoquinazolina-3(4h)-il)-piperidina-2,6-diona em tratamento de doenças inflamatórias e relacionadas ao sistema imune
|
JP6016892B2
(ja)
|
2011-04-29 |
2016-10-26 |
セルジーン コーポレイション |
セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法
|
US9320777B2
(en)
|
2011-05-13 |
2016-04-26 |
Bolder Biotechnology, Inc. |
Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
|
WO2013063290A1
(en)
|
2011-10-25 |
2013-05-02 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US10350139B2
(en)
|
2011-10-25 |
2019-07-16 |
Corning Incorporated |
Pharmaceutical glass packaging assuring pharmaceutical sterility
|
CA2853949A1
(en)
|
2011-11-01 |
2013-05-10 |
Celgene Corporation |
Methods for treating cancers using oral formulations of cytidine analogs
|
US8889630B2
(en)
|
2011-12-23 |
2014-11-18 |
Carlos Lopez |
Method for hair regrowth using Granulocyte-Colony Stimulating Factor
|
HUP1200172A2
(en)
|
2012-03-19 |
2013-10-28 |
Richter Gedeon Nyrt |
Methods for refolding g-csf from inclusion bodies
|
HUP1200171A1
(hu)
|
2012-03-19 |
2013-09-30 |
Richter Gedeon Nyrt |
Módszerek polipeptidek elõállítására
|
WO2013155347A1
(en)
|
2012-04-11 |
2013-10-17 |
Izumi Raquel |
Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
|
EP2841084B1
(en)
|
2012-04-24 |
2018-05-30 |
Biokine Therapeutics Ltd. |
Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
|
EP2867671B1
(en)
|
2012-06-29 |
2018-10-24 |
Celgene Corporation |
Methods for determining drug efficacy using cereblon-associated proteins
|
EP2870238A4
(en)
|
2012-07-05 |
2016-03-09 |
Ohio State Innovation Foundation |
COMPOSITIONS AND METHODS ASSOCIATED WITH VIRAL VACCINES
|
EP3613765A1
(en)
|
2012-08-03 |
2020-02-26 |
Dana-Farber Cancer Institute, Inc. |
Antibody against repulsive guidance molecule b (rgmb)
|
KR102146848B1
(ko)
|
2012-08-09 |
2020-08-21 |
셀진 코포레이션 |
3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법
|
CA2878954C
(en)
|
2012-08-09 |
2020-12-08 |
Benjamin M. Cohen |
Salts and solid forms of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
EA201590535A1
(ru)
|
2012-09-10 |
2015-07-30 |
Селджин Корпорейшн |
Способы лечения локально прогрессирующего запущенного рака молочной железы
|
US9968627B2
(en)
|
2013-03-26 |
2018-05-15 |
Celgene Corporation |
Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof
|
WO2014165482A1
(en)
|
2013-04-02 |
2014-10-09 |
Celgene Corporation |
Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
|
US9849066B2
(en)
|
2013-04-24 |
2017-12-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707153B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707154B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9839579B2
(en)
|
2013-04-24 |
2017-12-12 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717649B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700486B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9713572B2
(en)
|
2013-04-24 |
2017-07-25 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707155B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
WO2014197369A1
(en)
|
2013-06-06 |
2014-12-11 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
|
EP2815749A1
(en)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
EP3757130A1
(en)
|
2013-09-26 |
2020-12-30 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
WO2015057992A1
(en)
|
2013-10-16 |
2015-04-23 |
Izumi Raquel |
Btk inhibitors for hematopoietic mobilization
|
WO2015073727A1
(en)
|
2013-11-13 |
2015-05-21 |
Aequus Biopharma, Inc. |
Engineered glycoproteins and uses thereof
|
US20160340407A1
(en)
|
2014-01-14 |
2016-11-24 |
Dana-Farber Camcer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
|
US20150359810A1
(en)
|
2014-06-17 |
2015-12-17 |
Celgene Corporation |
Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
|
EP3160486B1
(en)
|
2014-06-27 |
2020-11-18 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
ES2940302T3
(es)
|
2014-08-22 |
2023-05-05 |
Celgene Corp |
Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos
|
WO2016146629A1
(en)
|
2015-03-16 |
2016-09-22 |
Arven Ilac Sanayi Ve Ticaret A.S. |
A process for preparing g-csf (granulocyte colony stimulating factor)
|
WO2016167291A1
(ja)
|
2015-04-13 |
2016-10-20 |
国立研究開発法人産業技術総合研究所 |
環状化サイトカイン及びその製法
|
ES2970117T3
(es)
|
2015-06-26 |
2024-05-27 |
Celgene Corp |
Métodos para el tratamiento de sarcoma de Kaposi o linfoma inducido por KSHV usando compuestos inmunomoduladores, y usos de biomarcadores
|
AU2016291817A1
(en)
|
2015-07-16 |
2018-02-22 |
Biolinerx Ltd. |
Compositions and methods for treating cancer
|
WO2017040387A2
(en)
|
2015-08-31 |
2017-03-09 |
Technovax, Inc. |
Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
|
US11229683B2
(en)
|
2015-09-18 |
2022-01-25 |
Bolder Biotechnology, Inc. |
Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
|
WO2017066561A2
(en)
|
2015-10-16 |
2017-04-20 |
President And Fellows Of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
AU2016342209B2
(en)
*
|
2015-10-19 |
2020-12-17 |
Sandoz Ag |
Improved coding sequence for human G-CSF
|
WO2017067959A1
(en)
|
2015-10-19 |
2017-04-27 |
Sandoz Ag |
Method for producing a recombinant protein with reduced impurities
|
EP3389652B1
(en)
|
2015-12-14 |
2022-09-28 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
JP6864296B2
(ja)
|
2015-12-14 |
2021-04-28 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
がんを処置する方法
|
ES2935834T3
(es)
|
2015-12-22 |
2023-03-10 |
X4 Pharmaceuticals Inc |
Métodos para tratar enfermedad de inmunodeficiencia
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
CA3010794A1
(en)
|
2016-01-08 |
2017-07-13 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
SG10202003099XA
(en)
|
2016-01-08 |
2020-05-28 |
Celgene Corp |
Antiproliferative compounds, and their pharmaceutical compositions and uses
|
CN113633634A
(zh)
|
2016-01-08 |
2021-11-12 |
细胞基因公司 |
2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的制剂
|
CA3014530A1
(en)
|
2016-02-23 |
2017-08-31 |
Biolinerx Ltd. |
Methods of treating acute myeloid leukemia
|
AU2017238054B2
(en)
|
2016-03-21 |
2023-10-19 |
Dana-Farber Cancer Institute, Inc. |
T-cell exhaustion state-specific gene expression regulators and uses thereof
|
SI3436019T1
(sl)
|
2016-04-01 |
2021-12-31 |
Signal Pharmaceuticals, Llc |
(1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-piran-4-il)amino)-8-((2,4, 6-triklorofenil)amino)-9h-purin-9-il)-1-metilcikloheksane-1-karboksamid in metode uporabe
|
MX2018011992A
(es)
|
2016-04-01 |
2019-01-24 |
Signal Pharm Llc |
Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos.
|
EP3440112A4
(en)
|
2016-04-08 |
2019-10-09 |
X4 Pharmaceuticals, Inc. |
METHOD FOR THE TREATMENT OF CANCER
|
EP3443107A1
(en)
|
2016-04-13 |
2019-02-20 |
Synthetic Genomics, Inc. |
Recombinant arterivirus replicon systems and uses thereof
|
EP3471726A4
(en)
|
2016-06-21 |
2019-10-09 |
X4 Pharmaceuticals, Inc. |
CXCR4 INHIBITORS AND USES THEREOF
|
US11332470B2
(en)
|
2016-06-21 |
2022-05-17 |
X4 Pharmaceuticals, Inc. |
CXCR4 inhibitors and uses thereof
|
JP7054529B2
(ja)
|
2016-06-21 |
2022-04-14 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
Cxcr4阻害剤およびその使用
|
WO2018013689A1
(en)
|
2016-07-13 |
2018-01-18 |
Celgene Corporation |
Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
|
WO2018013693A1
(en)
|
2016-07-13 |
2018-01-18 |
Celgene Corporation |
Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
|
EP3526332B1
(en)
|
2016-10-17 |
2024-06-26 |
Janssen Pharmaceuticals, Inc. |
Recombinant virus replicon systems and uses thereof
|
JP2020500536A
(ja)
|
2016-12-05 |
2020-01-16 |
シンセティック ジェノミクス インコーポレーテッド |
遺伝子発現増強のための組成物および方法
|
US20180258064A1
(en)
|
2017-03-07 |
2018-09-13 |
Celgene Corporation |
Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
|
SG11201911929XA
(en)
|
2017-06-21 |
2020-01-30 |
SHY Therapeutics LLC |
Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
JP2020526501A
(ja)
|
2017-06-30 |
2020-08-31 |
セルジーン コーポレイション |
2−(4−クロロフェニル)−n−{[2−(2,6−ジオキソピペリジン−3−イル)−1−オキソイソインドリン−5−イル]メチル}−2,2−ジフルオロアセトアミドの組成物及び使用法
|
US10543214B2
(en)
|
2017-10-04 |
2020-01-28 |
Celgene Corporation |
Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide
|
WO2019070827A1
(en)
|
2017-10-04 |
2019-04-11 |
Celgene Corporation |
PROCESSES FOR THE PREPARATION OF CIS-4 [2 - {(3S, 4R) -3-FLUOROOXAN-4-YL] AMINO) -8- (2,4,6-TRICHLOROANILINO) -9H-PURIN-9-YL] -1 -MÉTHYLCYCLOHEXANE-1-carboxamide
|
JP7046173B2
(ja)
*
|
2017-10-11 |
2022-04-01 |
エランコ・ユーエス・インコーポレイテッド |
ブタg-csf変異体とその使用
|
US11730736B2
(en)
|
2017-11-06 |
2023-08-22 |
Rapt Therapeutics, Inc. |
Anticancer agents
|
US11389531B2
(en)
|
2017-12-19 |
2022-07-19 |
Janssen Sciences Ireland Unlimited Company |
Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
|
EA202091513A1
(ru)
|
2017-12-19 |
2020-09-09 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Вакцины против вируса гепатита b (hbv) и их применение
|
EA202091516A1
(ru)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
|
KR20200111729A
(ko)
|
2018-01-19 |
2020-09-29 |
얀센 파마슈티칼즈, 인코포레이티드 |
재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
US20230078755A1
(en)
|
2018-12-19 |
2023-03-16 |
Shy Therapeutics, Llc |
Compounds that Interact with the RAS Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease
|
WO2020234742A1
(en)
|
2019-05-20 |
2020-11-26 |
Lupin Limited |
Granulocyte colony stimulating factor purification
|
WO2021091946A1
(en)
|
2019-11-05 |
2021-05-14 |
Celgene Corporation |
Combination therapy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
TW202406901A
(zh)
|
2022-04-14 |
2024-02-16 |
美商必治妥美雅史谷比公司 |
新穎gspt1化合物以及新穎化合物之使用方法
|
WO2024064646A1
(en)
|
2022-09-20 |
2024-03-28 |
Celgene Corporation |
Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same
|